Skip to content
Screener

Novavax NVAX Cost reimbursements — Total Revenue

Other product segments

Licensing, royalties, and other
$37.84M-83.4%
Upfront fee amortization
$8.73M-28.9%
Milestones amortization
$3.76M-33.6%
Royalties
$700K-86.0%
Support services
$265K-4.7%
Milestones
$0-100%
Upfront fee
$0-100%

Similar metrics at other companies

Marriott International logo
MARCost reimbursement revenue — Total Revenue
$4.84B+4.1%
Marriott International logo
MARNet fee revenues — Total Revenue
$1.4B+12.1%
Biogen logo
BIIBMS Product Revenues — Total Revenue
$963.3M-13.0%
Custom Truck One Source logo
CTOSTotal rental revenue — Total Revenue
$137.22M+18.0%
AES logo
AESRegulated Revenue — Total Revenue
$1.11B+13.1%
Gemini Space Station logo
GEMINet revenue — Total Revenue
$48.58M+38.3%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%—
Debt / equity1.5×—
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Licensing:
Milestones—$175,000—175,000
Royalties676—4,195—
Transition services and technology transfer:
Upfront fee amortization(1)8,72812,26820,83432,180
Milestones amortization(1)3,7625,6659,31314,808
Cost reimbursements22,6026,47950,32417,745
Total Sanofi licensing, royalties, and other revenue$35,768$199,412$84,666$239,733

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's cost reimbursements — total revenue?
Novavax (NVAX) reported cost reimbursements — total revenue of $22.6M in Q2 2026.
How has Novavax's cost reimbursements — total revenue changed year-over-year?
Novavax's cost reimbursements — total revenue increased by 248.9% year-over-year, from $6.48M to $22.6M.
What does cost reimbursements — total revenue mean?
This metric represents the total revenue recognized from the reimbursement of costs incurred by the company while performing research, development, or manufacturing activities on behalf of third-party partners or government entities. It reflects the financial recovery of operational expenditures associated with collaborative agreements or grant-funded programs. This revenue stream is indicative of the company's ability to leverage external funding to offset the financial burden of its clinical and commercial development pipeline.

Ask your AI about Novavax's cost reimbursements — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude